Circulating Tumor DNA as an Independent Predictor of treatment response in Metastatic Melanoma Patients Treated with Intratumoral and Cellular Therapies: A Retrospective Review
Circulating Tumor DNA as an Independent Predictor of Treatment Response in Metastatic Melanoma Patients Treated with Intratumoral and Cellular Therapies: A Retrospective Review
-
Clinical Trial Information
Trial Contact: Frankos, Marie; Caldwell, Chloe M
Trial Phone: 321.841.7303 ; (321)841.1107
-
IRB No: 22.246.11
Protocol Abbrev: Retrospective Review ctDNA
Principal Investigator: Sajeve Samuel Thomas, MD
Age Group: Adult
-
Objective
The primary objective is to compare ctDNA values to radiographic studies in patients treated with Intratumoral or cellular therapy for metastatic melanoma to determine whether there is a correlation between radiographic treatment response and trend in ctDNA values
-
Key Eligibility
1. Age 18 or older
2. Confirmed history of locally advanced, unresectable, or metastatic melanoma
3. Patients must have received cellular therapy or Intratumoral injection therapy
4. Selected by their HCP to receive ctDNA testing as part of their routine practice
